How Much Does Zepbound Cost in Pennsylvania in 2026?

Zepbound Retail Pricing Across Pennsylvania

The manufacturer list price set by Eli Lilly for Zepbound is $1,059 per month regardless of dose strength, and Pennsylvania retail pharmacies reflect this price for cash-pay patients with minimal variation across the state.

This price applies to a four-week supply of single-dose pens (four injections total). Whether you fill at a CVS in Philadelphia, a Rite Aid in Pittsburgh, or an independent pharmacy in State College, the out-of-pocket cost without insurance stays near the $1,059 mark. Some pharmacies charge slightly above list when dispensing fees are added. Wholesale acquisition cost does not vary by state because Eli Lilly sets uniform national pricing for branded tirzepatide.

For context on the drug's clinical value at this price point: SURMOUNT-1 (N=2,539) demonstrated that tirzepatide 15 mg produced 22.5% mean body weight reduction at 72 weeks compared to 2.4% for placebo 1. The 10 mg dose produced 19.5% mean weight loss, and even the lowest 5 mg dose achieved 15.0%. These results represent the largest weight reductions seen in any phase 3 obesity pharmacotherapy trial to date.

Pennsylvania ranks 26th nationally in adult obesity prevalence, with approximately 34% of adults classified as having obesity according to CDC behavioral risk factor data 2. Demand for GLP-1/GIP receptor agonists in the state has grown substantially since Zepbound received FDA approval in November 2023 for chronic weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity 3.

Pennsylvania Insurance Coverage for Zepbound

Most major commercial insurers operating in Pennsylvania now include Zepbound on their formularies, though coverage tiers and prior authorization requirements vary considerably between plans.

Highmark Blue Cross Blue Shield, the largest commercial insurer in Pennsylvania by enrollment, covers Zepbound on a specialty tier with prior authorization. Independence Blue Cross (the dominant plan in the Philadelphia metro area) added Zepbound to its commercial formulary in mid-2024. UPMC Health Plan, which covers over 4 million members across western and central Pennsylvania, provides coverage with step therapy requirements that typically mandate documentation of failed lifestyle intervention and, in some cases, prior trial of a GLP-1 receptor agonist alone.

Prior authorization criteria across Pennsylvania commercial plans generally require:

• Documented BMI ≥30, or BMI ≥27 with at least one comorbidity (type 2 diabetes, hypertension, dyslipidemia, or obstructive sleep apnea)
• Evidence of participation in a structured diet and exercise program for 3 to 6 months
• Prescriber attestation that the medication is for chronic weight management

The Endocrine Society's 2024 clinical practice guideline recommends pharmacotherapy as a first-line adjunct to lifestyle modification for patients with BMI ≥30, supporting earlier initiation than many insurers currently require 4.

Copays for commercially insured patients in Pennsylvania range from $25 to $150 per month depending on formulary tier, plan design, and whether the Lilly savings card is applied. Self-funded employer plans (ERISA plans) set their own coverage criteria, which may be more or less restrictive than state-regulated plans.

Pennsylvania Medicaid Coverage

Pennsylvania Medicaid (Medical Assistance) covers Zepbound with prior authorization, making it accessible to low-income residents who meet clinical criteria.

The Pennsylvania Department of Human Services manages the Medicaid formulary through its managed care organizations (MCOs), which include AmeriHealth Caritas, Highmark Wholecare, and UPMC for You, among others. Each MCO maintains its own prior authorization protocols, but the state requires coverage of FDA-approved medications when medically necessary criteria are met.

PA Medicaid prior authorization for Zepbound typically requires:

• BMI documentation from a clinical visit within the prior 90 days
• Diagnosis code for obesity (E66.01 or E66.09) or overweight with comorbidity
• Prescriber must be a physician, nurse practitioner, or physician assistant
• Some MCOs require a 90-day documented trial of metformin or orlistat before approving tirzepatide

Approval timelines vary. Standard requests process within 7 to 14 business days. Urgent requests can be expedited to 24 to 72 hours when the prescriber documents clinical necessity. Denials can be appealed through the MCO's internal process or through a Pennsylvania Fair Hearing.

For dual-eligible patients (those with both Medicare and Medicaid), Medicare Part D is the primary payer. Medicare Part D currently excludes anti-obesity medications from coverage under the Social Security Act, though legislative efforts to change this exclusion remain active in Congress as of 2026.

The Eli Lilly Zepbound Savings Card in Pennsylvania

Eli Lilly's manufacturer savings program reduces out-of-pocket costs to $25 per month for commercially insured patients whose plans cover Zepbound, and offers a $550 per month cap for patients whose insurance does not cover the medication.

Here is how the program works in Pennsylvania. Patients with commercial insurance that covers Zepbound present the savings card at the pharmacy alongside their insurance card. The card covers the difference between the patient's copay/coinsurance and $25, up to a maximum benefit of $150 per fill. Patients without insurance coverage (or whose plan explicitly excludes weight management drugs) pay no more than $550 per month through the card's cash-pay pathway.

Eligibility requirements:

• Must be 18 years or older
• Must have a valid prescription for Zepbound
• Cannot be enrolled in any federal or state healthcare program (Medicare, Medicaid, Tricare, VA)
• Must be a resident of the United States or Puerto Rico

Pennsylvania Medicaid beneficiaries cannot use the Lilly savings card. This restriction applies to all government-funded insurance. Patients on commercial plans offered through the Pennsylvania ACA marketplace (Pennie) are eligible if their plan is not subsidized through a government program.

The savings card program has no annual enrollment cap publicly disclosed by Lilly as of May 2026, though the company reserves the right to modify or discontinue the program. Patients should verify current terms at the Lilly website or through their pharmacy at each fill.

Compounded Tirzepatide in Pennsylvania

Compounded tirzepatide is available through licensed 503A compounding pharmacies in Pennsylvania at an average cost of $249 per month, significantly below the branded Zepbound price.

The legal status is straightforward. Under Pennsylvania law and federal regulation (the Drug Quality and Security Act of 2013), 503A pharmacies may compound tirzepatide when a patient-specific prescription exists and the drug is not being compounded from a commercially available product in shortage. The FDA's drug shortage list has included tirzepatide intermittently since 2023, which has permitted 503A compounding during shortage periods.

Critical considerations for Pennsylvania patients evaluating compounded tirzepatide:

Regulatory status: The FDA resolved the tirzepatide shortage designation in late 2024, then reinstated it in early 2025 for certain dose strengths. Compounding legality fluctuates with shortage status. Pennsylvania Board of Pharmacy oversight applies to all in-state 503A pharmacies, requiring patient-specific prescriptions and adherence to USP 797 sterile compounding standards.

Quality variability: Unlike FDA-approved Zepbound, compounded tirzepatide does not undergo the same batch testing, bioequivalence verification, or stability studies. A 2024 FDA warning letter cited multiple compounding pharmacies nationally for potency discrepancies ranging from 60% to 140% of labeled dose 5.

Cost comparison: At $249 per month versus $1,059 per month (cash pay) or $25 per month (with Lilly savings card and commercial insurance), the value proposition depends entirely on insurance status. For uninsured patients ineligible for the savings card, compounded tirzepatide saves approximately $300 per month compared to the savings card cash-pay pathway ($550/month).

Dr. Caroline Apovian, co-director of the Center for Weight Management and Wellness at Brigham and Women's Hospital, has stated: "Patients choosing compounded GLP-1 agonists should understand they are accepting unknown purity and potency in exchange for lower cost. The branded product has a known safety profile from trials enrolling over 10,000 participants."

Telehealth Access to Zepbound in Pennsylvania

Pennsylvania permits telehealth prescribing of Zepbound without requiring an in-person visit, expanding access across the state's rural and underserved areas.

The Pennsylvania Telemedicine Act (Act 56 of 2024) codified audio-visual telehealth visits as equivalent to in-person encounters for prescribing purposes, including controlled and non-controlled medications. Zepbound is not a controlled substance, so it faces no DEA-related prescribing restrictions via telehealth.

Multiple telehealth platforms now serve Pennsylvania patients seeking tirzepatide prescriptions. These platforms typically charge $99 to $199 for an initial consultation and $49 to $99 for monthly follow-ups. The prescription is then filled at either a retail pharmacy (at $1,059 cash or insurance-covered price) or through a partner compounding pharmacy.

Pennsylvania-specific telehealth requirements for Zepbound prescribing:

• The prescribing clinician must hold an active Pennsylvania medical license (MD, DO, NP, or PA)
• A synchronous audio-visual encounter is required for initial prescription (audio-only does not suffice for new prescriptions)
• Follow-up visits may be audio-only after the initial video consultation
• The clinician must document BMI, relevant comorbidities, and contraindication screening

For patients in rural Pennsylvania counties (Potter, Cameron, Sullivan, and others designated as Health Professional Shortage Areas), telehealth eliminates drives of 60 to 90 minutes to the nearest obesity medicine specialist. SURMOUNT-1 enrolled patients across 119 sites including several in Pennsylvania, confirming the drug's efficacy regardless of geographic access model 1.

Strategies to Minimize Zepbound Costs in Pennsylvania

The cheapest pathway to Zepbound in Pennsylvania depends on your insurance status, income level, and risk tolerance regarding compounded alternatives.

Tier 1: Commercially insured with coverage (lowest cost). Apply the Lilly savings card for a $25 monthly copay. This is the most affordable and safest option. Confirm coverage by calling the number on the back of your insurance card and asking for the formulary status of tirzepatide (Zepbound).

Tier 2: Commercially insured without coverage. Use the Lilly savings card cash-pay pathway at $550 per month. Simultaneously, ask your prescriber to submit a prior authorization or formulary exception request. Document BMI, comorbidities, and failed prior interventions.

Tier 3: Pennsylvania Medicaid. Submit prior authorization through your MCO. If denied, file an appeal citing the FDA-approved indication and your documented clinical criteria. Request a peer-to-peer review between your prescriber and the MCO's medical director.

Tier 4: Uninsured, ineligible for savings card. Compounded tirzepatide at approximately $249 per month through a Pennsylvania-licensed 503A pharmacy represents the lowest-cost option. Verify the pharmacy holds current Pennsylvania Board of Pharmacy licensure and complies with USP 797 standards.

The American Association of Clinical Endocrinology (AACE) 2023 obesity algorithm positions tirzepatide as a preferred agent for patients requiring ≥15% body weight reduction, noting that "cost should not be the sole barrier to evidence-based pharmacotherapy when clinical criteria are met" 6.

Dose Escalation and Long-Term Cost Implications

Zepbound's pricing structure means monthly cost stays constant at $1,059 regardless of dose, but clinical outcomes improve at higher doses, affecting the total treatment investment needed to reach goal weight.

The prescribing protocol begins at 2.5 mg weekly for four weeks (an initiation dose not expected to produce significant weight loss), then escalates to 5 mg weekly. Subsequent increases to 7.5 mg, 10 mg, 12.5 mg, and 15 mg occur at minimum four-week intervals based on tolerability. Most patients in SURMOUNT-1 reached the 10 mg or 15 mg maintenance dose by week 20 1.

Total cost projections for a 72-week treatment course (matching SURMOUNT-1 duration):

• Cash pay: $1,059 × 18 months = $19,062
• With Lilly savings card (insured): $25 × 18 months = $450
• With Lilly savings card (uninsured pathway): $550 × 18 months = $9,900
• Compounded tirzepatide: $249 × 18 months = $4,482

Weight regain after discontinuation is well-documented. The SURMOUNT-4 trial showed that patients who discontinued tirzepatide after 36 weeks of treatment regained approximately 14% of lost weight over the subsequent 52 weeks, while those continuing treatment maintained their losses 7. This finding has implications for long-term budgeting: most patients will require ongoing therapy to maintain results.

Pennsylvania patients should discuss maintenance dosing strategies with their prescriber. Some clinicians use the lowest effective maintenance dose (often 5 mg or 7.5 mg) after reaching goal weight, which does not reduce monthly cost for branded Zepbound but may reduce cost for compounded formulations that price by dose.

Pennsylvania-Specific Patient Assistance and Discount Programs

Beyond the Lilly savings card, several programs may reduce Zepbound costs for Pennsylvania residents meeting specific criteria.

Eli Lilly's Solutions Center offers free medication for patients with household income below 400% of the federal poverty level ($62,400 for a single individual in 2026) who lack prescription drug coverage. This program provides branded Zepbound at no cost for qualifying patients. Application requires income documentation and prescriber certification.

Pennsylvania PACE (Pharmaceutical Assistance Contract for the Elderly) covers residents aged 65 and older with income up to $14,500 (single) or $17,700 (married). PACENET extends coverage to those with income up to $27,500 (single) or $33,500 (married). These programs may cover Zepbound if it appears on their formulary, though anti-obesity medication coverage under PACE varies by year.

The 340B Drug Pricing Program benefits patients receiving care at federally qualified health centers (FQHCs) in Pennsylvania. The state has 44 FQHC organizations operating over 400 service sites. Patients receiving prescriptions through 340B-eligible entities may access Zepbound at substantially reduced acquisition cost, though savings pass-through to patients varies by site policy.

"The 340B program was designed to stretch scarce resources for safety-net providers," noted the Health Resources and Services Administration in its 2023 program guidance 8. Pennsylvania patients receiving care at community health centers should ask whether their site participates in 340B and whether obesity medications are included.